Dose-Finding Designs for HIV Studies (Q3078854): Difference between revisions

From MaRDI portal
Import240304020342 (talk | contribs)
Set profile property.
Set OpenAlex properties.
 
(2 intermediate revisions by 2 users not shown)
Property / Wikidata QID
 
Property / Wikidata QID: Q77412020 / rank
 
Normal rank
Property / cites work
 
Property / cites work: Estimating the Probability of Toxicity at the Recommended Dose Following a Phase I Clinical Trial in Cancer / rank
 
Normal rank
Property / cites work
 
Property / cites work: Miscellanea. A stopping rule for the continual reassessment method / rank
 
Normal rank
Property / cites work
 
Property / cites work: Continual Reassessment Method: A Likelihood Approach / rank
 
Normal rank
Property / cites work
 
Property / cites work: Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer / rank
 
Normal rank
Property / cites work
 
Property / cites work: Consistency of continual reassessment method under model misspecification / rank
 
Normal rank
Property / cites work
 
Property / cites work: Using a one-parameter model to sequentially estimate the root of a regression function. / rank
 
Normal rank
Property / cites work
 
Property / cites work: Q3930489 / rank
 
Normal rank
Property / full work available at URL
 
Property / full work available at URL: https://doi.org/10.1111/j.0006-341x.2001.01018.x / rank
 
Normal rank
Property / OpenAlex ID
 
Property / OpenAlex ID: W2032289930 / rank
 
Normal rank

Latest revision as of 10:16, 30 July 2024

scientific article
Language Label Description Also known as
English
Dose-Finding Designs for HIV Studies
scientific article

    Statements

    Dose-Finding Designs for HIV Studies (English)
    0 references
    0 references
    0 references
    0 references
    0 references
    1 March 2011
    0 references
    continual reassessment method
    0 references
    dose escalation
    0 references
    dose-finding studies
    0 references
    efficacy studies
    0 references
    HIV clinical trials
    0 references
    phase I trial
    0 references
    phase II trial
    0 references
    toxicity
    0 references

    Identifiers